NEW YORK (GenomeWeb) - Singulex said today that it has secured a Phase II Fast Track Small Business Innovation Research contract from the National Cancer Institute to develop biomarker assays to determine the effectiveness of potential cancer therapeutics.
 
The agreement extends a contract with NCI that Singulex originally signed in November 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.